Handok is partnering with sleep AI company A-Sleep to distribute the sleep rhythm recording digital medical device, ChronoTrack, in South Korea. This move aims to enhance Handok's portfolio, 'Handok Sleep Science,' by adding sleep recording and evaluation to its existing insomnia pharmaceuticals and digital therapeutics (DTx).
On August 20, Handok announced the signing of a distribution and sales agreement for ChronoTrack with A-Sleep. This agreement will enable Handok to establish a patient-centered sleep management system that connects sleep recording, treatment, and monitoring, expanding its sleep business from pharmaceuticals to digital healthcare.
Previously, A-Sleep formed a distribution partnership with Jungongdang for its sleep apnea testing software medical device, AppnoTrack. The ChronoTrack agreement reaffirms the commercialization pathway for digital medical devices through pharmaceutical distribution networks.
ChronoTrack is a digital medical device that records and monitors sleep patterns in daily life. Users only need to place their smartphone next to their bed, allowing AI to analyze sounds of breathing and movement during sleep, automatically recording 14 days of sleep data without the need for additional wearable devices or contact sensors.
Healthcare professionals can objectively assess patients' sleep conditions based on this data and continuously monitor treatment effectiveness. Additionally, its applicability under non-reimbursable legal provisions allows for immediate use in medical settings without the need for new billing codes, lowering barriers to adoption.
Handok is broadening its sleep business area into digital healthcare based on its existing pharmaceutical operations. Following the introduction of the prescription insomnia digital therapeutic device, SleepQ, in collaboration with Welt, based on its insomnia medication, Stilnox, the addition of ChronoTrack completes a comprehensive sleep management portfolio that encompasses recording, evaluation, treatment, and monitoring.
Through this, Handok is expected to accelerate the implementation of 'Handok Sleep Science,' which enables personalized treatment and long-term monitoring based on sleep data, moving beyond simple prescriptions.
Handok plans to expand the introduction of ChronoTrack in medical settings in collaboration with A-Sleep and raise awareness of the importance of sleep recording and evaluation through academic and educational activities. A-Sleep aims to leverage Handok's nationwide sales network to expedite the introduction to medical institutions.
Kim Mi-yeon, CEO of Handok, stated, "Sleep health can be improved when accurate diagnosis, appropriate treatment, and continuous management are interconnected. We will enhance sleep recording capabilities through ChronoTrack and implement Handok Sleep Science based on the synergy with insomnia pharmaceuticals and the digital therapeutic device, SleepQ."
On August 20, Handok announced the signing of a distribution and sales agreement for ChronoTrack with A-Sleep. This agreement will enable Handok to establish a patient-centered sleep management system that connects sleep recording, treatment, and monitoring, expanding its sleep business from pharmaceuticals to digital healthcare.
Previously, A-Sleep formed a distribution partnership with Jungongdang for its sleep apnea testing software medical device, AppnoTrack. The ChronoTrack agreement reaffirms the commercialization pathway for digital medical devices through pharmaceutical distribution networks.
ChronoTrack is a digital medical device that records and monitors sleep patterns in daily life. Users only need to place their smartphone next to their bed, allowing AI to analyze sounds of breathing and movement during sleep, automatically recording 14 days of sleep data without the need for additional wearable devices or contact sensors.
Healthcare professionals can objectively assess patients' sleep conditions based on this data and continuously monitor treatment effectiveness. Additionally, its applicability under non-reimbursable legal provisions allows for immediate use in medical settings without the need for new billing codes, lowering barriers to adoption.
Handok is broadening its sleep business area into digital healthcare based on its existing pharmaceutical operations. Following the introduction of the prescription insomnia digital therapeutic device, SleepQ, in collaboration with Welt, based on its insomnia medication, Stilnox, the addition of ChronoTrack completes a comprehensive sleep management portfolio that encompasses recording, evaluation, treatment, and monitoring.
Through this, Handok is expected to accelerate the implementation of 'Handok Sleep Science,' which enables personalized treatment and long-term monitoring based on sleep data, moving beyond simple prescriptions.
Handok plans to expand the introduction of ChronoTrack in medical settings in collaboration with A-Sleep and raise awareness of the importance of sleep recording and evaluation through academic and educational activities. A-Sleep aims to leverage Handok's nationwide sales network to expedite the introduction to medical institutions.
Kim Mi-yeon, CEO of Handok, stated, "Sleep health can be improved when accurate diagnosis, appropriate treatment, and continuous management are interconnected. We will enhance sleep recording capabilities through ChronoTrack and implement Handok Sleep Science based on the synergy with insomnia pharmaceuticals and the digital therapeutic device, SleepQ."
* This article has been translated by AI.
Copyright ⓒ Aju Press All rights reserved.